Article
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.
British journal of haematology - 1 Mar 2022
Chiappella Annalisa, Diop Fary, Agostinelli Claudio, Novo Mattia, Nassi Luca, Evangelista Andrea, Ciccone Giovannino, Di Rocco Alice, Martelli Maurizio, Melle Federica, Moia Riccardo, Motta Giovanna, Righi Simona, Santambrogio Elisa, Tucci Alessandra, Balzarotti Monica, Ladetto Marco, Pileri Stefano A, Gaidano Gianluca, Vitolo Umberto
Abstract excerpt
The prognostic role of TP53 disruption has been established in diffuse large B-cell lymphoma (DLBCL). Aim of this analysis was to correlate TP53 mutations by Sanger sequencing, cell of origin (COO) profile by Lymph2Cx panel on the NanoString platform and MYC, BCL2 and BCL6 overexpression or re-arrangements by immunohistochemistry (IHC) and fluorescent in-situ hybridization (FISH), with outcome in DLBCL patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
